טרוקאפ 200 מ"ג - Truqap 200 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EX Other protein kinase inhibitors |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | "TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy." |
| ×ת××××ת × ×× | Contraindications |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ר×ק×פ 200 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ASTRA ZENECA AB., SWEDEN |
| ×©× ××¢× ×ר×ש×× | ASTRAZENECA (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 5/2023. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 13/08/2024 |
השינוי האחרון נעשה בֹ־13 באוגוסט 2024 ב־15:46